Garnica Margoth Ramos, de Moraes Luciana Vieira, Rizzo Luiz Vicente, de Andrade Heitor Franco
Laboratory of Protozoology, Tropical Medicine Institute of São Paulo, University of São Paulo, São Paulo, SP, Brazil.
Immunology. 2005 Jul;115(3):399-406. doi: 10.1111/j.1365-2567.2005.02178.x.
In malaria, parasitaemia is controlled in the spleen, a multicomponent organ that undergoes changes in its cellular constituents to control the parasite. During this process, dendritic cells (DCs) orchestrate the positioning of effector cells in a timely manner for optimal parasite clearance. We have recently demonstrated that CXCL12 [stromal cell-derived factor-1 (CXCL12)] supplementation partially restores the ability to control parasitaemia in Plasmodium berghei-infected mice. In the present study, we investigated the nature of the DCs involved by flow cytometry and immunohistochemistry of CD11c(+) cells. Flow cytometry of bone marrow cells showed that infection with P. berghei did not alter the proportion of CD11c(+) cells present in this haematopoietic compartment, while CXCL12 supplementation of naïve uninfected mice induced only minor increases in the population of CD11c(+) cells. In the spleen, P. berghei infection alone resulted in an increase in CD11c(+) cells as compared with naïve animals. Exogenously administered CXCL12 in the absence of infection resulted in a significant expansion of the splenic CD11c(+) population, and this effect was even more pronounced in infected and supplemented mice. Immunohistochemistry revealed that CD11c(+) cells infiltrated the perivascular areas and marginal zone of the spleen in infected animals treated with CXCL12, suggesting that this chemokine induces homing of CD11c(+) dendritic cells to the splenic compartment. Our results show that small amounts of CXCL12 supplementation are effective in recruiting DCs to the spleens of both uninfected and infected mice, suggesting the participation of CXCL12 and CD11c(+) cells in the establishment of an adequate environment in the spleen for malaria control.
在疟疾中,疟原虫血症在脾脏中得到控制,脾脏是一个多组分器官,其细胞成分会发生变化以控制寄生虫。在此过程中,树突状细胞(DCs)会及时协调效应细胞的定位,以实现最佳的寄生虫清除。我们最近证明,补充CXCL12 [基质细胞衍生因子-1(CXCL12)] 可部分恢复伯氏疟原虫感染小鼠控制疟原虫血症的能力。在本研究中,我们通过对CD11c(+) 细胞进行流式细胞术和免疫组织化学分析,研究了所涉及的DCs的性质。对骨髓细胞进行流式细胞术分析表明,感染伯氏疟原虫不会改变该造血区室中CD11c(+) 细胞的比例,而对未感染的单纯小鼠补充CXCL12只会使CD11c(+) 细胞群体略有增加。在脾脏中,与单纯小鼠相比,仅感染伯氏疟原虫就导致CD11c(+) 细胞增加。在未感染的情况下外源性给予CXCL12会导致脾脏CD11c(+) 群体显著扩增,并且这种效应在感染并补充CXCL12的小鼠中更为明显。免疫组织化学显示,在用CXCL12治疗的感染动物中,CD11c(+) 细胞浸润到脾脏的血管周围区域和边缘区,这表明这种趋化因子可诱导CD11c(+) 树突状细胞归巢至脾脏区室。我们的结果表明,少量补充CXCL12可有效将DCs募集到未感染和感染小鼠的脾脏中,这表明CXCL12和CD11c(+) 细胞参与在脾脏中建立适当的环境以控制疟疾。